ChemoCentryx, Inc. (NASDAQ:CCXI) Q2 2018 Earnings Conference Call - Final Transcript
Aug 09, 2018 • 05:00 pm ET
a second indication for avacopan in C3G is well underway and we have filed an amendment to double the number of patients. Clinical development of our second renal disease asset, the CCR2 inhibitor, CCX140, is ongoing in 2 patient populations of primary FSGS. We intend also to start a comprehensive randomized controlled study of avacopan for the treatment of the dermatological indication of HS later this year, as we expand our value creation beyond kidney disease.
We intend the second half -- we entered the second half of this year with an impressively strong balance sheet with more than $200 million in cash and investments. In conclusion, my belief is that 2018 to date shows marked progress for our enterprise. And that progress reveals that positive forces are in motion for ChemoCentryx. We believe powerful momentum is building, and we look forward to an exciting future.
With that, I will now turn the call back over to the operator and look forward to your questions. Operator?